Show simple item record

dc.contributor.authorKutti Sridharan, Gurusaravanan
dc.contributor.authorKotagiri, Rajesh
dc.contributor.authorChandiramani, Vijay H
dc.contributor.authorMohan, Babu P
dc.contributor.authorVegunta, Rathnamitreyee
dc.contributor.authorVegunta, Radhakrishna
dc.contributor.authorRokkam, Venkata R P
dc.date.accessioned2020-10-07T01:55:25Z
dc.date.available2020-10-07T01:55:25Z
dc.date.issued2020-07
dc.identifier.citationSridharan, G. K., Kotagiri, R., Chandiramani, V. H., Mohan, B. P., Vegunta, R., Vegunta, R., & Rokkam, V. R. (2020). COVID-19 and avoiding ibuprofen. How good is the evidence?. American journal of therapeutics, 27(4), e400-e402.en_US
dc.identifier.issn1075-2765
dc.identifier.pmid32366740
dc.identifier.doi10.1097/MJT.0000000000001196
dc.identifier.urihttp://hdl.handle.net/10150/647641
dc.description.abstractIbuprofen is an over-the-counter medication that is used widely for the treatment of pain and fever during COVID-19 pandemic. A concern was raised regarding the safety of ibuprofen use because of its role in increasing ACE2 levels within the Renin-Angiotensin-Aldosterone system. ACE2 is the coreceptor for the entry of SARS-CoV-2 into cells, and so, a potential increased risk of contracting COVID-19 disease and/or worsening of COVID-19 infection was feared with ibuprofen use. However, available data from limited studies show administration of recombinant ACE2 improves lung damage caused by respiratory viruses, suggesting ibuprofen use may be beneficial in COVID-19 disease. At this time, there is no supporting evidence to discourage the use of ibuprofen.en_US
dc.language.isoenen_US
dc.publisherLIPPINCOTT WILLIAMS & WILKINSen_US
dc.rightsCopyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en_US
dc.subjectCOVID-19en_US
dc.subjectibuprofenen_US
dc.subjectSARS-CoV-2en_US
dc.subjectcoronavirusen_US
dc.subjectpandemicen_US
dc.titleCOVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?en_US
dc.typeArticleen_US
dc.identifier.eissn1536-3686
dc.contributor.departmentUniv Arizona, Banner Univ Med Ctr, Dept Internal Meden_US
dc.identifier.journalAMERICAN JOURNAL OF THERAPEUTICSen_US
dc.description.noteNo embargo COVID-19en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal accepted manuscripten_US
dc.source.journaltitleAmerican journal of therapeutics
dc.source.volume27
dc.source.issue4
dc.source.beginpagee400
dc.source.endpagee402
refterms.dateFOA2020-10-07T01:55:26Z
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
COVID -19 final.pdf
Size:
152.9Kb
Format:
PDF
Description:
Final Accepted Manuscript

This item appears in the following Collection(s)

Show simple item record